Pacific Cancer Medical Center | Anaheim, CA

Research site

(Unclaimed)

Location

1801 W Romneya Drive #203, Anaheim, California, United States of America

Site insights

Top conditions

Top treatments

Docetaxel

Gemcitabine

Everolimus

Dexamethasone

Pembrolizumab

Palonosetron

Paclitaxel

Cyclophosphamide

Lenalidomide

Satraplatin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 91 total trials

A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer (REZILIENT1)

CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal g...

Active, not recruiting

EGFR Exon 20 Mutation

Non Small Cell Lung Cancer

Drug: CLN-081

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Active, not recruiting

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Drug: Fulvestrant

Drug: Dexamethasone Mouth Rinse

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 ye...

Active, not recruiting

Multiple Myeloma

Drug: Dexamethasone

Drug: Lenalidomide

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Active, not recruiting

Leukemia, B-cell

Small Lymphocytic Lymphoma

Drug: Pirtobrutinib

Drug: Ibrutinib

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive...

Enrolling

Colorectal Neoplasms

Drug: levoleucovorin

Drug: leucovorin

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Or...

Active, not recruiting

Part 2：B-cell Malignancies

Part 1：r/r B-cell Malignancies

Drug: Orelabrutinib (ICP-022)

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or meta...

Active, not recruiting

Nonsmall Cell Lung Cancer

Drug: HS-10296

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted...

Active, not recruiting

Non Hodgkin Lymphoma

Drug: HMPL-523

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to...

Enrolling

Chemotherapy-induced Nausea and Vomiting

Drug: Palonosetron HCl Buccal Film 0.5 mg

Drug: IV Palonosetron 0.25 mg

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) befor...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Placebo

Drug: Pemetrexed

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbocic...

Enrolling

Breast Cancer

Drug: Alpelisib

Drug: Fulvestrant

Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 (Mevrometostat) in Adult Patients With Relapsed/Refractory Small Cell Lung Cancer...

Enrolling

Follicular Lymphoma (FL)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Drug: Enzalutamide

Drug: Mervometostat (PF-06821497)

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regim...

Active, not recruiting

Head and Neck Cancer

Drug: Pembrolizumab

Drug: Cetuximab

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metast...

Active, not recruiting

Metastatic Nonsquamous Non-Small Cell Lung Cancer

Metastatic Squamous Non-Small Cell Lung Cancer

Drug: Placebo

Drug: Paclitaxel

Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation

The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safe...

Enrolling

KRAS/NRAS Mutation

Metastatic Colorectal Cancer

Drug: Bevacizumab

Drug: FOLFOX

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irino...

Active, not recruiting

Metastatic Colorectal Cancer

Colorectal Cancer

Drug: Bevacizumab

Drug: Onvansertib

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

Active, not recruiting

Chemotherapy-induced Thrombocytopenia

Other: Placebo

Biological: Romiplostim

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or br...

Enrolling

Chemotherapy-induced Thrombocytopenia

Drug: Placebo

Drug: Romiplostim